Methods and pharmaceutical compositions for treating chronic kidney disease

Through the combination of doxazosin, praxol and metoprolol, the GPCR signaling pathway is regulated, and the problem of poor treatment effect of diabetic nephropathy in the prior art is solved, significantly reducing proteinuria and improving glomerular filtration rate, delaying Diabetic nephropathy progresses and shows good safety and tolerance.

CN116113408BActive Publication Date: 2024-11-22CHENGDU SHENGYUAN WENDING BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202180056137.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-08-10
Filing Date
2021-07-14
Publication Date
2024-11-22
Estimated Expiration
2041-07-14

AI Technical Summary

Technical Problem

The existing treatment methods for diabetic nephropathy are poor in preventing and controlling disease progression, and common drugs cannot effectively prevent the occurrence of trace proteinuria, especially in patients with normal blood pressure and no proteinuria.

Method used

The combination of doxazosin, praxol and metoprolol is used to significantly reduce proteinuria and improve glomerular filtration rate by regulating the GPCR signaling pathway, thereby delaying the development of diabetic nephropathy to end-stage renal disease.

Benefits of technology

In the spontaneous chronic diabetic rhesus monkey model, it significantly reduces proteinuria, improves glomerular filtration rate, delays the progress of diabetic nephropathy, and shows good safety and tolerance, and its efficacy is comparable to that of the clinical first-line drug valsartan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116113408B_ABST
    Figure CN116113408B_ABST
Patent Text Reader

Abstract

The present application relates to a method and a pharmaceutical composition for treating chronic kidney disease. The method and the pharmaceutical composition of the present application involve the combined use of doxazosin, pramipexole and metoprolol (or their pharmaceutically acceptable salts), which can significantly improve chronic kidney disease, significantly reduce urine albumin excretion rate UACR, significantly improve glomerular filtration rate eGFR, and effectively delay the development of renal function impairment to end-stage renal failure.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of disease treatment and medicine, and specifically to the treatment of chronic kidney disease, especially diabetic nephropathy. Background Art

[0002] Chronic kidney disease (CKD) is a disease that seriously affects human health, especially the health of the elderly. According to statistics, the prevalence of CKD in adults in the United States is as high as 11.3%, while the prevalence of CKD in China is estimated to be about 10%. Diabetes and hypertension are considered to be the main predisposing factors of CKD.

[0003] Diabetes is one of the common diseases that affect human health. In 2015, there were nearly 420 million diabetic patients worldwide. It is estimated that the number of diabetic patients will reach 640 million by 2040. It is estimated that 20-40% of diabetic patients may develop diabetic nephropathy. Diabetic nephropathy is the main complication of diabetes, also known as DKD (Diabetic Kidney Disease) or DN (Diabetic Nephropathy) in the literature. Diabetic nephropathy is a lesion of abnormal kidney structure and function caused by chronic microvascular lesions of diabetes. The clinical manifestations are mainly hypertension, proteinuria, edema, etc. The pathological manifestations are damage to glomerular blood vessels, sclerosis to form nodular lesions, which in turn cause abnormal renal function and persistent urine protein, and eventually lead to renal failure and end-stage renal disease (ESRD), which has a high mortality rate.

[0004] DKD is a complex disease with both environmental and genetic factors involved. The reported occurrence and development mechanisms are very complex, involving multiple pathological changes such as oxidative stress, inflammation, renal function damage, renal interstitial fibrosis, hemodynamic changes, genetic factors, etc. Among them, oxidative stress plays an important role in the pathogenesis and is considered to be closely related to the occurrence and development of DKD.

[0005] At present, the management strategy of DKD is mainly to achieve optimal blood sugar and blood pressure control, correct dyslipidemia, reverse insulin resistance, and reduce proteinuria (using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers), thereby delaying renal function decline and reducing cardiovascular risk events. The main means of treating DKD is to inhibit the activation of the renin-angiotensin-aldosterone system (RAAS) by using angiotensin-converting enzyme inhibitors ACEI and / or angiotensin receptor antagonists ARB. Valsartan is a commonly used ARB in clinical practice. It improves the selective permeability of the glomeruli and keeps the radius of the glomerular filtration pore unchanged, thereby continuously reducing urinary albumin without causing a decrease in the glomerular filtration rate (eGFR). It is currently a commonly used drug for the treatment of DKD. However, the existing treatments and drugs are still poor in terms of preventing and controlling the progression and effectiveness of diabetic nephropathy. Studies have shown that ARB does not increase the risk of myocardial infarction and can further reduce the risk of heart failure and stroke, but the study also found that ARB cannot reduce all-cause mortality in included patients. At the same time, for diabetic patients with normal blood pressure and no proteinuria, the use of ACEI or ARB drugs cannot prevent the occurrence of microalbuminuria.

[0006] Therefore, there is an urgent need for the development of new drugs that can effectively treat CKD and / or DKD and effectively delay the progression of CKD / DKD to ESRD. Summary of the invention

[0007] Therefore, one object of the present application is to provide a better or alternative treatment method and medicine for treating chronic kidney disease (especially diabetic nephropathy).

[0008] The present inventors surprisingly found that the combination of doxazosin, pramipexole and metoprolol has a significant therapeutic effect in the treatment of chronic kidney disease, especially diabetic nephropathy.

[0009] Therefore, the first aspect of the present application relates to a pharmaceutical composition for treating chronic kidney disease, which comprises doxazosin (or a pharmaceutically acceptable salt thereof), pramipexole or a pharmaceutically acceptable salt thereof and metoprolol (or a pharmaceutically acceptable salt thereof) as active ingredients.

[0010] The second aspect of the present application relates to the use of a combination of doxazosin (or a pharmaceutically acceptable salt thereof), pramipexole (or a pharmaceutically acceptable salt thereof) and metoprolol (or a pharmaceutically acceptable salt thereof) in the preparation of a pharmaceutical composition for treating chronic kidney disease, especially diabetic nephropathy, in a subject in need thereof.

[0011] The third aspect of the present application relates to the use of a combination of doxazosin (or a pharmaceutically acceptable salt thereof), pramipexole (or a pharmaceutically acceptable salt thereof) and metoprolol (or a pharmaceutically acceptable salt thereof) in treating chronic kidney disease, especially diabetic nephropathy, in a subject in need thereof.

[0012] The fourth aspect of the present application relates to a method for treating chronic kidney disease, especially diabetic nephropathy, comprising administering a therapeutically effective amount of doxazosin (or a pharmaceutically acceptable salt thereof), pramipexole (or a pharmaceutically acceptable salt thereof) and metoprolol (or a pharmaceutically acceptable salt thereof) to a subject in need thereof.

[0013] The inventors used rhesus monkeys with spontaneous chronic diabetic nephropathy as an animal model to simulate human DKD patients, and unexpectedly found that the combination of doxazosin, pramipexole and metoprolol can significantly reduce proteinuria and significantly improve glomerular filtration rate in the animal model, thereby controlling or delaying the development of DKD to end-stage renal disease (ESRD), and no adverse reactions related to administration were observed during the administration period, showing good safety. Therefore, the drug combination of the present application represents a new therapy for chronic kidney disease, especially diabetic nephropathy. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] The specific implementation methods of the present application are described in detail below in conjunction with the accompanying drawings, wherein:

[0015] Figure 1 The figure shows the comparison of the changes of albuminuria (UACR, urinary albumin excretion rate) of each group of rhesus monkeys at 30 days of drug treatment (D30) (**, p<0.01 compared with the placebo group; *, p<0.05 compared with the placebo group);

[0016] Figure 2 The figure shows the comparison of the changes of albuminuria (UACR, urinary albumin excretion rate) of each group of rhesus monkeys at 58 days of treatment (D58) (**, p<0.01 compared with the placebo group; *, p<0.05 compared with the placebo group);

[0017] Figure 3 The changes in eGFR of each group of rhesus monkeys after administration are shown (eGFR of each group: 30-59 ml / min / 1.73 m 2 For analysis, the DOX+PMP+MTP1# experimental group and the DOX+PMP+MTP2# experimental group were combined into one group for analysis; *, the difference between the DOX+PMP+MTP group and the placebo group was p<0.05). DETAILED DESCRIPTION

[0018] The present application relates to a combination of multiple GPCR drugs and corresponding combined treatment methods.

[0019] G protein (guanine nucleotide-binding protein) coupled receptors (GPCRs) are a large class of transmembrane proteins that regulate intracellular signal transduction and are essential for intracellular homeostasis. Existing literature studies have shown that the GPCR signaling pathway is related to diabetes-induced superoxide generation (Du, Y., et al., Adrenergic and serotonin receptors affect reti / l superoxide generation in diabetic mice: Relationship to capillary degeneration and permeability. 2015.29(5): p.2194.). Although oxidative stress is an important mechanism in the development of DKD, GPCR drugs that regulate diabetes-induced superoxide production may theoretically have a certain effect on the development of DKD. However, current research is limited to the pathogenesis level, and the therapeutic effect of GPCR drugs on DKD remains to be studied. In addition, GPCR drugs cover hundreds of different substances, and it is also difficult to screen out clinically effective drugs for DKD.

[0020] In addition, most of the current animal models of diabetic nephropathy are rodents, such as drug-induced mouse models, spontaneous db / db mice, ob / ob mice, Agout mutant mice and New Zealand obese mice, as well as transgenic mouse models, etc. However, due to the complex pathogenesis of diabetic nephropathy and the many links involved, the damage to renal function in these animal models is difficult to accurately reflect the course of DKD in patients and is difficult to be used to evaluate the effectiveness of disease treatment methods. Nonhuman primates are extremely similar to humans in physiology, biochemistry and systems biology. Many studies have reported that the disease characteristics of spontaneous chronic diabetic nephropathy in rhesus monkeys are very similar to those of clinical DKD patients, and they also show moderate to severe increase in urine albumin and decreased eGFR. Therefore, spontaneous chronic diabetic nephropathy in rhesus monkeys provides an important research tool for CKD / DKD research and new drug development (Najafian, B., et al., Glomerulopathy in spontaneously obese rhesus monkeys with type 2 diabetes: astereological study. Diabetes Metab Res Rev, 2011. 27(4): p.341-7. Liang Y, Yang Z, et al. Diabetic Kidney Disease (DKD) in Nonhuman Primates (NHP's) is Comparable to Humans for Glomerular Filtration Rate (GFR), Histology and High Risk Factors. ADA 2017).

[0021] Taking into account the limitations of rodent models in studying human diabetic nephropathy, the inventors used spontaneous chronic diabetic nephropathy rhesus monkeys as animal models to simulate human patients and conducted a large number of detailed studies and extensive screening of numerous GPCR drugs. The results unexpectedly found that some GPCR drugs had significant therapeutic effects on DKD when combined. Specifically, it has been found that the combination of doxazosin, pramipexole and metoprolol can significantly reduce proteinuria (UACR) in CKD-EPI rated G3 stage and combined with moderate to severe proteinuria rhesus monkey animal models, significantly improve glomerular filtration rate eGFR, inhibit DKD from developing to end-stage renal disease (ESRD), and its efficacy is comparable to valsartan, a commonly used drug in the clinical front line. Based on this, the present application discloses a pharmaceutical composition for treating chronic kidney disease, especially DKD, and its medical use.

[0022] 1. Pharmaceutical Composition

[0023] The first aspect of the present application provides a pharmaceutical composition for treating chronic kidney disease, especially diabetic nephropathy, comprising doxazosin (or a pharmaceutically acceptable salt thereof), pramipexole (or a pharmaceutically acceptable salt thereof) and metoprolol (or a pharmaceutically acceptable salt thereof) as active ingredients.

[0024] Certain terms are used in the specification, examples and claims of this application. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this application belongs.

[0025] The terms "including", "comprising", and "having" are used in an inclusive, open sense, meaning that additional elements may be included in addition to those specified. The terms "such as" and "for example" as used herein are non-limiting and are used for illustrative purposes only. "Including" and "including but not limited to" are used interchangeably.

[0026] The term "or", when used herein, should be understood to mean "and / or", unless the context clearly indicates otherwise.

[0027] The term "treat" refers to inhibiting a disease, disorder and / or symptom of a subject, such as hindering its progression; and alleviating a disease, disorder and / or symptom, such as causing regression of a disease, disorder and / or symptom. Treating a disease or disorder includes ameliorating at least one symptom of a particular disease or disorder, even if the underlying pathophysiology is not affected. In particular, in this application, "treat" also encompasses the meaning of reducing the risk of developing a disease by taking a drug, that is, "treat" includes both prevention before the onset of the disease and alleviation, inhibition and cure of the disease after the onset of the disease.

[0028] The term "pharmaceutical composition" refers to a combination of multiple substances with specific medical or biological uses, which are usually expected to have a therapeutic or preventive effect on a specific disease after being administered to a subject. The pharmaceutical composition may contain only the specified active ingredients (biologically active substances), or it may be provided together with a conventional pharmaceutically acceptable carrier for various purposes. The term "composition" in this application should be interpreted in a broad sense. As an implementation of the pharmaceutical composition of the present application, for example, the specified active ingredients (and optional pharmaceutically acceptable carriers) can be mixed together to provide a mixture in which the components are indistinguishable. As another implementation of the pharmaceutical composition of the present application, each specified active ingredient can also be separately packaged into small portions, and these small independent packages can be combined and accommodated together in a larger container to provide the "pharmaceutical composition" of the present application.

[0029] The terms "active ingredient" and "biologically active substance" refer to molecules and other agents of biologically, physiologically or pharmaceutically active substances that act in a patient or subject to treat a disease or condition (e.g., diabetic nephropathy). The term is used relative to terms such as "pharmaceutically acceptable carrier", "excipient", "adjuvant", etc. "Active ingredient" (or "biologically active substance") includes, but is not limited to, pharmaceutically acceptable salts and prodrugs thereof. These agents can be acids, bases or salts; they can be neutral molecules, polar molecules or molecular complexes capable of hydrogen bonding; they can be prodrugs in the form of ethers, esters, amides, etc., which are bioactivated when administered to a patient or subject.

[0030] The term "doxazosin" as used herein refers to Doxazosin (DOX for short), whose IUPAC name is (RS)-2-[4-(2,3-dihydro-1,4-benzodioxene-2-carbonyl)piperazin-1-yl]-6,7-dimethoxy-4-amine (molecular formula C 23 H 25 N5O5, molecular weight: 451.475 g / mol) as follows:

[0031]

[0032] The term "doxazosin" also encompasses its isotopically labeled compounds, or its optical isomers, geometric isomers, tautomers or isomer mixtures, or its prodrugs (ie, compounds that give the above molecules through in vivo reactions).

[0033] Doxazosin is a marketed drug approved by major pharmaceutical regulatory agencies (such as the FDA). It is a selective α1 receptor antagonist that inhibits the binding of norepinephrine (released from sympathetic nerve endings) to α-1 receptors on the vascular smooth muscle cell membrane and is commonly used to treat essential hypertension.

[0034] The pharmaceutical composition of the present application may contain doxazosin or a pharmaceutically acceptable salt thereof as an active ingredient. Most commercially available doxazosin drugs are in the form of salts, particularly mesylate salts thereof, such as doxazosin mesylate controlled release tablets (Cardovac) provided by Pfizer Pharmaceuticals, doxazosin mesylate tablets provided by Hangzhou Kangenbei Pharmaceutical Co., Ltd., and the like.

[0035] The term "pramipexole" as used herein refers to the English name Pramipexole (PMP for short), the IUPAC name of which is (S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine (molecular formula C 10 H 17 N3S, molecular weight: 211.324 g / mol) is as follows:

[0036]

[0037] The term "pramipexole" also encompasses its isotopically labeled compounds, or its optical isomers, geometric isomers, tautomers or isomer mixtures, or its prodrugs (ie, compounds that react in vivo to give the above molecules).

[0038] Pramipexole is a marketed drug approved by major pharmaceutical regulatory agencies (such as the FDA). It is an antihistamine that acts as a dopamine receptor D2 / D3 agonist and is clinically used to treat Parkinson's disease, either alone (without levodopa) or in combination with levodopa. In the literature, pramipexole is sometimes referred to as "Mirapa" or "Mirapex", "Mirapexin", "Sifrol", etc.

[0039] The pharmaceutical composition of the present application may contain pramipexole or a pharmaceutically acceptable salt thereof as an active ingredient. Most commercially available pramipexole is in the form of a salt, particularly its hydrochloride, such as pramipexole hydrochloride tablets (Senforol) provided by Boehringer Ingelheim Pharmaceuticals.

[0040] The term "metoprolol" as used herein refers to the English name Metoprolol (MTP for short), the IUPAC name (RS)-1-[4-(2-methoxyethyl)phenoxy]-3-[(propan-2-yl)amino]propan-2-ol (molecular formula C 15 H 25 NO3, molecular weight 267.37g / mol) as follows:

[0041]

[0042] The term "metoprolol" also encompasses its isotopically labeled compounds, or its optical isomers, geometric isomers, tautomers or isomer mixtures, or its prodrugs (ie, compounds that give the above molecules by in vivo reactions).

[0043] Metoprolol is a drug approved by major pharmaceutical regulatory agencies (such as the FDA) and is a selective adrenergic β1 receptor blocker commonly used to treat hypertension and angina pectoris. The pharmaceutical composition of the present application may contain metoprolol or a pharmaceutically acceptable salt thereof as an active ingredient. The commercially available drugs of metoprolol are mostly in the form of salts, particularly tartrate, such as metoprolol tartrate tablets (Betaloc) provided by AstraZeneca Pharmaceuticals Co., Ltd., metoprolol tartrate controlled-release tablets (Lijunning) provided by Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., etc.

[0044] The active ingredients (doxazosin, pramipexole, metoprolol) contained in the composition of the present application can be replaced by their pharmaceutically acceptable salts. The term "pharmaceutically acceptable salt" of a compound refers to a salt that is pharmaceutically acceptable and has the desired pharmacological activity of the parent compound. Pharmaceutically acceptable salts used herein are salts formed with pharmaceutically acceptable acids or bases. Pharmaceutically acceptable acids include, but are not limited to, inorganic acids, such as hydrochloric acid, sulfuric acid, phosphoric acid, pyrophosphoric acid, hydrobromic acid or nitric acid, and organic acids, such as citric acid, fumaric acid, maleic acid, malic acid, ascorbic acid, succinic acid, tartaric acid, benzoic acid, acetic acid, methanesulfonic acid, ethanesulfonic acid, salicylic acid, stearic acid, benzenesulfonic acid or p-toluenesulfonic acid. Pharmaceutically acceptable bases include hydroxides of alkali metals (such as sodium or potassium) and alkaline earth metals (such as calcium or magnesium), and organic bases, such as alkylamines, arylamines or heterocyclic amines. For the avoidance of doubt, a "pharmaceutically acceptable salt" of an active ingredient described in the present application also includes a pharmaceutically acceptable salt formed from an isotope-labeled compound of the active ingredient, or an optical isomer, geometric isomer, tautomer or isomer mixture thereof, or a prodrug thereof.

[0045] Pharmaceutically acceptable salts can be synthesized from parent compounds containing basic or acidic moieties by conventional chemical methods. Typically, these salts can be prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of an appropriate base or acid in water or in an organic solvent or in a mixture of the two; typically, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred. A list of salts can be found in Remington's Pharmaceutical Sciences 18th edition (Mack Publishing Company, 1990). For example, salts may include, but are not limited to, hydrochlorides, tartrates, mesylates, etc. of the compounds described in this application.

[0046] It should be understood that all references to various active ingredients or pharmaceutically acceptable salts include solvent addition forms (solvates, such as hydrates, ethanol solvates, acetone solvates, etc.) or various crystal forms thereof (such as amorphous forms, polymorphs, etc.) of the same active ingredient or salt.

[0047] The content of doxazosin (or its pharmaceutically acceptable salt), pramipexole (or its pharmaceutically acceptable salt) and metoprolol (or its pharmaceutically acceptable salt) in the pharmaceutical composition of the present application can be adjusted according to actual needs. For example, the content or ratio of each drug in the pharmaceutical composition can be changed according to the administration method of the pharmaceutical composition (oral or injection, etc.).

[0048] In some embodiments, the pharmaceutical composition of the present application generally comprises 0.5 to 45 parts by weight (preferably 1 to 10 parts by weight) of pramipexole or a pharmaceutically acceptable salt thereof, 5 to 160 parts by weight (preferably 5 to 80 parts by weight) of doxazosin or a pharmaceutically acceptable salt thereof, and 50 to 2000 parts by weight (preferably 100 to 1000 parts by weight) of metoprolol or a pharmaceutically acceptable salt thereof.

[0049] In the pharmaceutical composition of the present application, the amount of pramipexole or a pharmaceutically acceptable salt thereof is generally 0.5 to 45 parts by weight, for example, 0.5 to 42 parts by weight, 0.5 to 40 parts by weight, 0.5 to 35 parts by weight, 0.5 to 30 parts by weight, 0.5 to 25 parts by weight, 0.5 to 20 parts by weight, 0.5 to 15 parts by weight, 0.5 to 10 parts by weight, 1 part to 45 parts by weight, 1 part to 42 parts by weight, 1 part to 40 parts by weight, 1 part to 35 parts by weight, 1 part to 30 parts by weight, 1 part to 25 parts by weight, 1 part to 20 parts by weight, 1 part to 25 parts by weight, 1 to 15 parts by weight, 1 to 10 parts by weight, 2 to 45 parts by weight, 2 to 40 parts by weight, 2 to 35 parts by weight, 2 to 30 parts by weight, 2 to 25 parts by weight, 2 to 20 parts by weight, 2 to 15 parts by weight, 2 to 10 parts by weight, 5 to 45 parts by weight, 5 to 40 parts by weight, 5 to 35 parts by weight, 5 to 30 parts by weight, 5 to 25 parts by weight, 5 to 20 parts by weight, 5 to 15 parts by weight, 5 to 10 parts by weight, 10 to 40 parts by weight, 10 to 30 parts by weight, 10 to 25 parts by weight, etc. In a preferred embodiment of the present application, the content of pramipexole or its pharmaceutically acceptable salt is 1 to 10 parts by weight.

[0050] In the pharmaceutical composition of the present application, the usual amount of doxazosin or a pharmaceutically acceptable salt thereof is 5 to 160 parts by weight, for example, 5 to 150 parts by weight, 5 to 130 parts by weight, 5 to 120 parts by weight, 5 to 100 parts by weight, 5 to 80 parts by weight, 5 to 60 parts by weight, 5 to 50 parts by weight, 5 to 40 parts by weight, 10 to 150 parts by weight, 10 to 130 parts by weight, 10 to 120 parts by weight, 10 to 100 parts by weight, 10 to 80 parts by weight, 10 to 60 parts by weight, 5 to 50 parts by weight, 10 to 40 parts by weight, 0 parts by weight, 15 parts by weight to 160 parts by weight, 15 parts by weight to 150 parts by weight, 15 parts by weight to 130 parts by weight, 15 parts by weight to 120 parts by weight, 15 parts by weight to 100 parts by weight, 15 parts by weight to 80 parts by weight, 15 parts by weight to 60 parts by weight, 15 parts by weight to 50 parts by weight, 15 parts by weight to 40 parts by weight, 20 parts by weight to 160 parts by weight, 20 parts by weight to 150 parts by weight, 20 parts by weight to 130 parts by weight, 20 parts by weight to 120 parts by weight, 20 parts by weight to 100 parts by weight, 20 parts by weight to 80 parts by weight, 20 parts by weight to 60 parts by weight, 20 parts by weight to 50 parts by weight, 20 parts by weight to 40 parts by weight, etc. In a preferred embodiment of the present application, the content of doxazosin or its pharmaceutically acceptable salt is 5 parts by weight to 80 parts by weight.

[0051] In the pharmaceutical composition of the present application, the amount of metoprolol or its pharmaceutically acceptable salt is generally 50 parts by weight to 2000 parts by weight, for example, 50 parts by weight to 1800 parts by weight, 50 parts by weight to 1600 parts by weight, 50 parts by weight to 1500 parts by weight, 50 parts by weight to 1300 parts by weight, 50 parts by weight to 1200 parts by weight, 50 parts by weight to 1000 parts by weight, 50 parts by weight to 8 ... 100 parts by weight to 1500 parts by weight, 100 parts by weight to 1300 parts by weight, 100 parts by weight to 1200 parts by weight, 100 parts by weight to 1000 parts by weight, 100 parts by weight to 800 parts by weight, 100 parts by weight to 600 parts by weight, 100 parts by weight to 500 parts by weight, 50 parts by weight to 400 parts by weight, 100 parts by weight to 1800 parts by weight, 100 parts by weight to 1600 parts by weight, 100 parts by weight to 1500 parts by weight, 100 parts by weight to 1300 parts by weight, 100 parts by weight to 1200 parts by weight, 100 parts by weight to 1000 parts by weight, 100 parts by weight to 800 parts by weight, 100 parts by weight to 600 parts by weight. parts by weight, 100 parts by weight to 500 parts by weight, 100 parts by weight to 400 parts by weight, 150 parts by weight to 2000 parts by weight, 150 parts by weight to 1800 parts by weight, 150 parts by weight to 1600 parts by weight, 150 parts by weight to 1500 parts by weight, 150 parts by weight to 1300 parts by weight, 150 parts by weight to 1200 parts by weight, 150 parts by weight to 1000 parts by weight, 150 parts by weight to 800 parts by weight , 150 to 600 parts by weight, 200 to 2000 parts by weight, 200 to 1800 parts by weight, 200 to 1600 parts by weight, 200 to 1500 parts by weight, 200 to 1300 parts by weight, 200 to 1200 parts by weight, 200 to 1000 parts by weight, 200 to 800 parts by weight, 200 to 600 parts by weight, etc. In a preferred embodiment of the present application, the content of doxazosin or a pharmaceutically acceptable salt thereof is 100 to 1000 parts by weight.

[0052] In the pharmaceutical composition of the present application, if the weight of doxazosin or a pharmaceutically acceptable salt thereof is taken as a reference (=1), the weight ratio of metoprolol or a pharmaceutically acceptable salt thereof to doxazosin or a pharmaceutically acceptable salt thereof is generally in the range of 0.3:1 to 400:1, for example, it may be greater than or equal to 0.4:1, 0.5:1, 0.6:1, 0.7:1, 0.8:1, 0.9:1, 1:1, 1.5:1, 2:1, 3:1, 4:1, 5:1, 10:1, 12.5:1 or 15:1, preferably greater than or equal to 1:1, 1.5:1, 2:1, 3:1, 4:1, 5:1, 10:1, 12.5:1 or 15:1. 1, 4:1, 5:1, 10:1, 12.5:1 or 15:1, and may be less than or equal to 350:1, 300:1, 250:1, 200:1, 150:1, 100:1, 90:1, 80:1, 70:1, 60:1, 50:1, 40:1, 30:1 or 20:1, preferably less than or equal to 100:1, 90:1, 80:1, 70:1, 60:1, 50:1, 40:1, 30:1 or 20:1; similarly, based on the weight of doxazosin or its pharmaceutically acceptable salt as a reference (=1), then pramipexole or its The weight ratio of the pharmaceutically acceptable salt to doxazosin or its pharmaceutically acceptable salt is generally in the range of 0.003:1 to 10:1, for example, it may be greater than or equal to 0.004:1, 0.005:1, 0.006:1, 0.007:1, 0.008:1, 0.009:1, 0.01:1, 0.015:1, 0.02:1, 0.03:1, 0.04:1, 0.05:1, 0.06:1, 0.07:1, 0.08:1, 0.1:1 or 0.2:1, preferably greater than or equal to 0.005:1, 0.006:1, 0.007:1, 0.008:1, 0.009:1, 0.01:1, 0.015:1, 0.02:1, 0.03:1, 0.04:1, 0.05:1, 0.06:1, 0.07:1, 0.08:1, 0.1:1 or 0.2:1. 1, 0.007:1, 0.008:1, 0.009:1, 0.01:1, 0.015:1, 0.02:1, 0.03:1, 0.04:1, 0.05:1, 0.06:1, 0.07:1, 0.08:1 or 0.1:1, and can be less than or equal to 9:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 0.9:1, 0.6:1, 0.5:1, 0.4:1 or 0.3:1, preferably less than or equal to 1:1, 0.9:1, 0.6:1, 0.5:1 or 0.4:1.

[0053] 2. Drug Dosage Form

[0054] In some embodiments, the pharmaceutical composition of the present application can be provided as a form of bulk drug (e.g., a uniform mixture or an independent package of each component). In other embodiments, the pharmaceutical composition of the present application can be formulated into various pharmaceutical dosage forms (preparations) by adding a pharmaceutically acceptable carrier as required. For this purpose, various liquid or solid fillers, diluents, excipients, solvents or encapsulating materials can be used as "pharmaceutically acceptable carriers". In the present application, the phrase "pharmaceutically acceptable" refers to compounds, compositions, polymers and other materials that are compatible with other components of the present application composition and are suitable for contacting with human and animal tissues without excessive toxicity, stimulation, allergic reactions or other problems or complications within the scope of reasonable medical judgment. In some preferred embodiments, the pharmaceutically acceptable carrier is pyrogen-free. Some examples of materials that can be used as pharmaceutically acceptable carriers include: (1) sugars such as lactose, glucose and sucrose; (2) starches such as corn starch and potato starch; (3) cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate; (4) powdered tragacanth; (5) maltodextrin; (6) gelatin; (7) talc; (8) excipients such as cocoa butter and suppository wax; (9) peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil and soy oil. oils; (10) glycols such as propylene glycol; (11) polyols such as glycerol, sorbitol, mannitol and polyethylene glycol; (12) esters such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) phosphate buffer solution; (21) other non-toxic compatible substances used in pharmaceutical preparations.

[0055] The pharmaceutical composition of the present application can be formulated into a dosage form suitable for oral administration, parenteral administration (including subcutaneous, intramuscular, cortical and intravenous), bronchial administration, intravitreal injection or nasal administration as needed. Among them, preferably, the pharmaceutical composition of the present application is formulated into a dosage form (preparation) suitable for oral administration.

[0056] If a solid carrier is used, the preparation can be tableted, placed in a hard gel capsule in the form of a powder or granules, or made into a lozenge or tablet form. Solid carriers can include conventional excipients, such as adhesives, fillers, tableting lubricants, disintegrants, wetting agents, etc. If necessary, the tablet can be coated by conventional technology film coating. If a liquid carrier is used, the preparation can be in the form of a syrup, emulsion, soft gel capsule, a sterile carrier for injection, an aqueous or non-aqueous liquid suspension, or can be a dry product reconstituted with water or other appropriate carriers before use. Liquid preparations can contain conventional additives, such as suspending agents, emulsifiers, wetting agents, non-aqueous carriers (including edible oils), preservatives, and flavoring agents and / or coloring agents. For parenteral administration, the carrier usually includes at least sterile water for the most part, but saline solutions, glucose solutions, etc. can also be used. Injectable suspensions can also be used, in which case conventional suspending agents can be used. Conventional preservatives, buffer agents, etc. can also be added to parenteral dosage forms.

[0057] Dosage forms suitable for parenteral injection may include physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions and sterile powders for sterile injectable solutions or dispersions. Examples of suitable aqueous and non-aqueous carriers, diluents, solvents include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, etc.), suitable mixtures thereof, vegetable oils (e.g., olive oil) and injectable organic esters (e.g., ethyl oleate).

[0058] These pharmaceutical dosage forms may also include various excipients, such as preservatives, wetting agents, emulsifiers and dispersants. The inhibition of the effects of microorganisms may be ensured by various antibacterial and antifungal agents (e.g., parabens, chlorobutanol, phenol, sorbic acid, etc.). Isotonic agents may also be included, such as sugar, sodium chloride, etc. The absorption of injectable pharmaceutical dosage forms may be extended by using delayed absorption agents (e.g., aluminum monostearate and gel).

[0059] Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is mixed with at least one inert excipient (or carrier) (e.g., sodium citrate or dicalcium phosphate), which may also include: (a) fillers or admixtures (e.g., starch, lactose, sucrose, glucose, mannitol and silicic acid); (b) binders (e.g., carboxymethylcellulose, alginate, gelatin, polyvinyl pyrrolidone, sucrose and gum arabic); (c) humectants (e.g., glycerol); (d) disintegrants (e.g., agar); The invention can be prepared by mixing (a) agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain synthetic silicates, sodium carbonate); (e) solution retarder (e.g., paraffin); (f) absorption promoter (e.g., quaternary ammonium compounds); (g) wetting agents (e.g., cetyl alcohol and glycerol monostearate); (h) adsorbents (e.g., kaolin and bentonite) and (i) lubricants (e.g., talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate) or mixtures thereof.

[0060] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or lactose as well as high molecular weight polyethylene glycols.

[0061] Solid dosage forms (e.g., tablets, dragees, capsules, pills and granules) can be prepared using coatings and shells (e.g., enteric coatings and others known in the art). They can contain opacifiers, and they can also be compositions that release the active compound or various active compounds in a delayed manner in a certain part of the intestine. Examples of useful embedding compositions are polymeric substances and waxes. The active ingredient can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.

[0062] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, dispersions, syrups and elixirs. In addition to the active compound, the liquid dosage form may include inert diluents (e.g., water or other solvents) commonly used in the art, solubilizers and emulsifiers (e.g., ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide ammonium), oils (specifically, cottonseed oil, groundnut oil, corn oil, olive oil, castor oil, sesame oil), glycerol, tetrahydrofuran alcohol, polyethylene glycol and fatty acid esters of sorbitan or mixtures of these substances, etc.

[0063] Besides these inert diluents, pharmaceutical dosage forms may also include, for example, wetting agents, emulsifying and suspending agents, perfuming agents, flavoring agents, and perfuming agents.

[0064] In addition to the active compounds, suspensions may contain suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol, sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.

[0065] The pharmaceutical dosage forms of the present application also include ointments, powders, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any required preservatives, buffers or propellants.

[0066] The amount of active ingredients in the pharmaceutical composition and dosage form can be appropriately determined by those skilled in the art as needed. For example, each active ingredient is generally present in the pharmaceutical composition or dosage form in a therapeutically effective amount.

[0067] For example, the pharmaceutical composition of the present application can be formulated into an oral dosage form (eg, an oral dosage form for 2 to 3 times a day or a long-acting sustained-release oral preparation), an intravenous injection form, or an intramuscular injection form.

[0068] In a preferred embodiment of the present application, the pharmaceutical composition of the present application is an oral dosage form. In a further preferred embodiment of the present application, the pharmaceutical composition of the present application is an oral dosage form once a day, an oral dosage form 2 to 3 times a day, or a long-acting sustained-release oral preparation.

[0069] In a preferred embodiment of the present application, the pharmaceutical composition of the present application is a dosage form for oral administration. In a further preferred embodiment of the present application, the pharmaceutical composition of the present application is a daily oral dosage form.

[0070] III. Uses of pharmaceutical compositions and pharmaceutical dosage forms

[0071] It has been found that the pharmaceutical composition and pharmaceutical dosage form of the present application can be used to treat chronic kidney disease (CKD), especially diabetic nephropathy (DN or DKD).

[0072] Therefore, the second aspect of the present application relates to the use of a combination of doxazosin (or a pharmaceutically acceptable salt thereof), pramipexole (or a pharmaceutically acceptable salt thereof) and metoprolol (or a pharmaceutically acceptable salt thereof) in the preparation of a pharmaceutical composition for treating chronic kidney disease, especially diabetic nephropathy, in a subject in need thereof.

[0073] The third aspect of the present application relates to the use of a combination of doxazosin (or a pharmaceutically acceptable salt thereof), pramipexole (or a pharmaceutically acceptable salt thereof) and metoprolol (or a pharmaceutically acceptable salt thereof) in treating chronic kidney disease, especially diabetic nephropathy, in a subject in need thereof.

[0074] The fourth aspect of the present application relates to a method for treating chronic kidney disease, especially diabetic nephropathy, which comprises administering a therapeutically effective amount of doxazosin (or a pharmaceutically acceptable salt thereof), pramipexole (or a pharmaceutically acceptable salt thereof) and metoprolol (or a pharmaceutically acceptable salt thereof) to a subject in need thereof.

[0075] The pharmaceutical composition and dosage form of the present application are suitable for the treatment of diabetic nephropathy at all stages, and are also suitable for preventive treatment before the onset of the disease.

[0076] The "patient" or "subject" treated by the method of the present application may refer to a human or a non-human animal, such as a primate. Preferably, the "patient" or "subject" is a human.

[0077] The treatment methods of the present application involve the combined use of multiple active ingredients, also known as "combination therapy" or "combination therapy". The "combination therapy" or "combination therapy" refers to the administration of multiple active ingredients described in the present application so that they work together to provide a beneficial effect. The beneficial effects of the above combination include, but are not limited to, the combined effects of the pharmacodynamics or pharmacodynamics produced by the combination of the above active ingredients. The combined administration of these active ingredients is usually completed within a specified period of time (usually minutes, hours, days or weeks, depending on the doctor's judgment). "Combination therapy" or "combination therapy" is intended to include the administration of these active ingredients in a sequential manner, that is, each of the active ingredients is administered at different times, and also includes the administration of these active ingredients in a substantially simultaneous manner, or the administration of at least two of these active ingredients. Substantially simultaneous administration can be accomplished, for example, by administering a single capsule to the host, wherein a fixed ratio of each active ingredient is contained in the capsule, or by administering multiple capsules to the host, wherein each capsule is filled with one of the active ingredients. The sequential or substantially simultaneous administration of each active ingredient may be affected by any suitable route, including, but not limited to, oral, intravenous, intramuscular, and direct absorption via mucosal tissue. The active ingredients may be administered by the same route or by different routes. For example, the first active ingredient in the selected combination may be administered by intravenous injection, while the other active ingredients in the combination may be administered orally. Alternatively, for example, all active ingredients may be administered orally, or all active ingredients may be administered by intravenous injection. The order of administration of the active ingredients is not strictly limited.

[0078] "Combination therapy" or "combination therapy" also includes the combination of the active ingredients described above with other biologically active ingredients and non-drug treatments (e.g., surgical treatment or mechanical treatment). When the combination therapy further includes non-drug treatment, the non-drug treatment can be performed at any appropriate time as long as the beneficial effects of the combination of the active ingredients and the non-drug treatment can be achieved. For example, in appropriate circumstances, the beneficial effects can still be achieved after the non-drug treatment is temporarily stopped from the administration of the active ingredients, and the stopping may be for several days or even weeks.

[0079] In order to achieve the desired effect, it is usually necessary to administer a therapeutically effective amount of the pharmaceutical composition or dosage form of the present application or each active ingredient alone to a patient or subject.

[0080] The phrase "therapeutically effective amount" is a term recognized in the art. In certain embodiments, the term refers to an amount necessary or sufficient to eliminate, reduce, or maintain the goal of a particular treatment regimen. The effective amount may vary depending on factors such as the disease or condition being treated, the specific targeting construct being administered, the size of the subject, or the severity of the disease or condition. One of ordinary skill in the art or a physician can determine the effective amount of a particular compound empirically without excessive experimentation. In certain embodiments, the therapeutically effective amount of a therapeutic agent used in vivo may depend on many factors, including: the manner and method of administration; any other materials contained in the drug in addition to the agent. In vitro or in vivo assays may be used to help determine the optimal dosage range.

[0081] In some embodiments of the present application, for an adult with a normal body weight of about 60 kg, when the pharmaceutical dosage form or pharmaceutical composition of the present application is orally used, the daily dose range of doxazosin or a pharmaceutically acceptable salt thereof can be 0.5 mg to 16 mg, for example, 0.5 mg to 15 mg, 0.5 mg to 13 mg, 0.5 mg to 12 mg, 0.5 mg to 10 mg, 0.5 mg to 8 mg, 0.5 mg to 6 mg, 0.5 mg to 5 mg, 0.5 mg to 4 mg, 1 mg to 15 mg, 1 mg to 13 mg, 1 mg to 12 mg, 1 mg to 10 mg. g, 1mg to 8mg, 1mg to 6mg, 1mg to 5mg, 1mg to 4mg, 1.5mg to 16mg, 1.5mg to 15mg, 1.5mg to 13mg, 1.5mg to 12mg, 1.5mg to 10mg, 1.5mg to 8mg, 1.5mg to 6mg, 1.5mg to 5mg, 1.5mg to 4mg, 2mg to 16mg, 2mg to 15mg, 2mg to 13mg, 2mg to 12mg, 2mg to 10mg, 2mg to 8mg, 2mg to 6mg, 2mg to 5mg, 2mg to 4mg, etc. In a preferred embodiment of the present application, the daily dose range of doxazosin or its pharmaceutically acceptable salt can be about 2mg. In another preferred embodiment of the present application, the daily dose of doxazosin is about 4mg. .

[0082] In some embodiments of the present application, for an adult with a normal body weight of about 60 kg, when the pharmaceutical dosage form or pharmaceutical composition of the present application is orally used, the daily dose range of pramipexole or a pharmaceutically acceptable salt thereof can be 0.05 mg to 4.5 mg, for example, 0.05 mg to 4.2 mg, 0.05 mg to 4 mg, 0.05 mg to 3.5 mg, 0.05 mg to 3 mg, 0.05 mg to 2.5 mg, 0.05 mg to 2 mg, 0.05 mg to 1.5 mg, 0.05 mg to 1 mg, 0.1 mg to 4.5 mg, 0.1 mg to 4.2 mg, 0.1 mg to 4 mg, 0.1 mg to 3.5 mg, 0.1 mg to 3 mg, 0.1 mg to 2.5 mg, 0.1 In some embodiments, the present invention relates to a pharmaceutical composition comprising the following: a) a pharmaceutical composition comprising: ... In a preferred embodiment of the present application, the daily dose of pramipexole is about 0.0625 mg. In another preferred embodiment of the present application, the daily dose of pramipexole is about 0.125 mg.

[0083] In some embodiments of the present application, for an adult with a normal body weight of about 60 kg, when the pharmaceutical dosage form or pharmaceutical composition of the present application is taken orally, the daily dose range of metoprolol or its pharmaceutically acceptable salt may be 5 mg to 200 mg, for example, 5 mg to 180 mg, 5 mg to 160 mg, 5 mg to 150 mg, 5 mg to 130 mg, 5 mg to 120 mg, 5 mg to 100 mg, 5 mg to 80 mg, 5 mg to 60 mg, 5 mg to 50 mg, 5 mg to 40 mg, 10 mg to 180 mg, 10 mg to 160 mg, 10 mg to 150 mg, 10 mg to 130 mg, 10 mg to 120 mg, 10 mg to 100 mg, 5 mg to 80 mg, 5 mg to 60 mg, 5 mg to 50 mg, 5 mg to 40 mg, 10 mg to 180 mg, 10 mg to 160 mg, 10 mg to 150 mg, 10 mg to 130 mg, 10 mg to 120 mg, 10 mg to 1 In a preferred embodiment of the present application, the daily dose range of metoprolol or its pharmaceutically acceptable salt is 10mg to 100mg. In a preferred embodiment of the present application, the daily dose of metoprolol is about 20 mg. In another preferred embodiment of the present application, the daily dose of metoprolol is about 40 mg.

[0084] The above daily dose can be administered continuously and periodically, for example, once every 2 hours, every 6 hours, every 8 hours, every 12 hours, or about every 24 hours. Preferably, the daily dose can be administered to the patient in the form of 2 to 3 times a day, or administered using a sustained-release tablet. The oral daily doses of the above three active ingredients vary greatly, which is determined by the in vivo pharmacokinetic of each active ingredient.

[0085] Those skilled in the art will appreciate that when the pharmaceutical composition of the present application is formulated into other dosage forms suitable for intravenous infusion or intramuscular injection, the dosage range of each active ingredient may be different from the oral dosage range given above. Those skilled in the art or doctors can make reasonable determinations based on in vivo and in vitro experiments and taking into account the different pharmacokinetic characteristics of various routes of administration.

[0086] In a preferred embodiment of the present application, the pharmaceutical composition of the present application is used for primate subjects, especially human subjects.

[0087] Those skilled in the art will appreciate that the various aspects of the present application described herein can be combined in various ways that are clear to those skilled in the art without departing from the subject matter and ideas of the present application. Such combinations are also included in the scope of the present application. For example, the dosage range of certain components involved in the present application includes any combination of any lower limit and any upper limit mentioned in the specification, and also includes any range composed of the specific content of the component in each specific embodiment as an upper limit or a lower limit combination; all these ranges are included in the scope of the present application. In addition, each feature of the present application listed in the specification can be combined with any other feature of the invention, and such combinations are also within the scope of the disclosure of the present application.

[0088] Example

[0089] The inventor used rhesus monkeys with spontaneous chronic diabetic nephropathy as experimental animals to verify the effectiveness and drug safety and tolerability of the combination of three marketed GPCR signaling pathway drugs, doxazosin (DOX), pramipexole (PMP) and metoprolol (MTP), for diabetic nephropathy. Valsartan, a common first-line drug for DKD, was used as a positive control in the experiment.

[0090] 1. Experimental Materials

[0091] Specifically, the following three marketed drugs were used as test products in the experiment:

[0092]

[0093] Note: The monkey dose and human dose can be converted using the body surface area method or the in vivo drug concentration exposure.

[0094] Test sample 1:

[0095] Name or abbreviation (English name): Doxazosin mesylate (DOX)

[0096] Purity: 98% HPLC

[0097] Production unit: Shanghai Ziqi Biotechnology Co., Ltd.

[0098] Test sample 2:

[0099] Name or abbreviation (English name): Pramipexole 2HCL Monohydrate (PMP)

[0100] Purity: 99.55% HPLC

[0101] Production unit: Shanghai Ziqi Biotechnology Co., Ltd.

[0102] Test sample 3

[0103] Name or abbreviation (English name): Metoprolol tartratesalt (MTP)

[0104] Purity: 98% HPLC

[0105] Manufacturer: Aladdin (Shanghai) Reagent Co., Ltd.

[0106] Positive control drug: Valsartan

[0107] Name or abbreviation (English name): Valsartan

[0108] Manufacturer: Shanghai BiDe Pharmaceutical Technology Co., Ltd.

[0109] 2. Specific Experimental Plan

[0110] Experimental Animals:

[0111] Animal Species: Rhesus monkey, Macaca mulatta (Rhesus Macaque).

[0112] Grade: General. The quarantine before the test is qualified, including physical examination, 2 tuberculosis tests, parasites, salmonella, shigella and B virus tests.

[0113] Animal identification: stainless steel plate with Arabic numerals on the collar, chest tattoo

[0114] Supplier: Ya'an Primi Biotechnology Co., Ltd.

[0115] Production license number: SCXK (Chuan) 2019-027

[0116] The test system complies with AAALAC requirements and GLP standards

[0117] Feeding environment:

[0118] Environmental level: General level. Temperature: 18-26℃. Relative humidity: 40% to 70%. Ventilation: No less than 8 air changes per hour, 100% fresh air (no air circulation). Lighting time: Automatic lighting, light and dark alternation every 12 hours, turn off the lights at 7:30PM, turn on the lights at 7:30AM the next day. Animal cage: 850*900*2365mm double-layer stainless steel cage. Stocking density: 1 per cage.

[0119] A total of 16 rhesus monkeys with spontaneous chronic diabetic nephropathy (DKD) were selected for the experiment. The inclusion criteria were as follows:

[0120] 1) 16 males / females, aged 14 to 24 years (equivalent to 40 to 75 years old adults); 14 males, weighing 7 to 13 kg; 2 females: 6 to 8 kg

[0121] 2) Diabetes duration of more than 2 years: fasting blood glucose (FPG): greater than 4.8mmol / L, vs. age-matched controls (4.1±0.3mmol / L);

[0122] 3) CKD-EPI grade G3a to G3b: eGFR: 30 to 59 ml / min / 1.73 m 2 vs age-matched controls: 92±11ml / min / 1.73m 2 ; or moderate to severe increase in proteinuria (A2 to A3) is urine albumin / creatinine ratio (UACR): 15mg / g to 350mg / g (4 to 6 hours urine collection), vs 3±2mg / g in age-matched controls.

[0123] 4) Normal blood pressure, grade 1 or grade 2 hypertension (consistent with clinical patient standards).

[0124] Exclusion criteria were as follows:

[0125] 1) Severe liver dysfunction

[0126] 2) Any other diseases that may affect the evaluation of drug efficacy

[0127] Table 1 below shows the baseline period - the underlying causes and characteristics of spontaneous chronic diabetic nephropathy in rhesus monkeys in each group.

[0128]

[0129] Grouping and dosing regimen:

[0130] This trial set up a DOX+PMP+MTP group (n=8), a Valsartan group (n=4) and a placebo group (n=4). The DOX+PMP+MTP group was further divided into experimental group 1# and experimental group 2#. The specific dosing regimen of each group is described below, and the route of administration is oral administration. The baseline period is 1 month, followed by continuous oral administration for 58 days.

[0131] 1# Experimental group: 4 animals

[0132] D0 to D14: DOX+PMP+MTP: 0.133+0.002+0.833 mg / kg, twice a day;

[0133] D15 to D28: DOX+PMP+MTP: 0.266+0.002+1.667 mg / kg, twice daily;

[0134] D29 to D58: DOX+PMP+MTP: 0.266+0.004+0.833 mg / kg, DOX and MTP twice a day, PMP once a day

[0135] 2# Experimental group: 4 animals

[0136] D0 to D14: DOX+PMP+MTP: 0.133+0.002+0.833 mg / kg, twice daily

[0137] D15 to D28: DOX+PMP+MTP: 0.133+0.002+1.667 mg / kg, twice daily

[0138] D29 to D58: DOX+PMP+MTP: 0.266+0.002+1.667 mg / kg, twice daily

[0139] Valsartan group: 4 animals, dose 2.67 mg / kg (equivalent to clinical equivalent dose 40 to 80 mg), daily administration from D0 to D58; once a day in the first to second weeks of the administration period, and twice a day in the third to eighth weeks.

[0140] Placebo group: 4 animals, given drinking water or fruit, and observed for 58 consecutive days.

[0141] In order to further evaluate the effect of each active ingredient in the pharmaceutical composition on the efficacy, another group of rhesus monkeys with spontaneous chronic diabetic nephropathy were selected for the experiment, in which the effects of the DOX+MTP composition and placebo were compared in parallel.

[0142] The specific dosing regimen of each group is described below, wherein the route of administration is oral administration. The baseline period is 1 month, followed by continuous oral administration for 60 days.

[0143] DOX+MTP experimental group: 4 animals

[0144] D0 to D30: DOX + MTP: 0.266 mg / kg + 1.667 mg / kg, twice daily

[0145] D30 to D58: DOX + MTP: 0.532 mg / kg + 3.334 mg / kg, twice daily

[0146] Placebo group: 3 animals, given drinking water or fruit, and observed for 60 consecutive days.

[0147] Table 1A below shows the baseline underlying etiology and characteristics of each experimental animal in the additional experiments.

[0148]

[0149] 3. Main Observation Indicators and Monitoring Methods

[0150] 1. Main efficacy indicators

[0151] Glomerular filtration rate eGFR: Detect creatinine (Cr-P), urea nitrogen (BUN), and cystatin (CysC) to calculate the eGFR value. Detect once at the baseline before administration and at the specified time after administration (such as D14, D28, D45, and D58, etc.). Referring to the reference (Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612), the eGFR calculation formula is as follows:

[0152] eGFR male =135×min(Cr / 0.9,1) -0.207 ×max(Cr / 0.9,1) -0.601 ×min(CysC / 0.8,1) -0.375 ×max(CysC / 0.8,1) -0.711 ×0.995 Age×3

[0153] eGFR female =135×min(Cr / 0.7,1) -0.284 ×max(Cr / 0.7,1) -0.601 ×min(CysC / 0.8,1) -0.375 ×max(CysC / 0.8,1) -0.711 ×0.995 Age×3 ×0.969

[0154] Urinary albumin excretion rate UACR: 4h / 6h urine collection, detection of urine microalbumin (Malb) and urine creatinine (Cr-U), calculation to obtain UACR value. Detect once before administration and at a specified time after administration (e.g., once on day 30 and once on D58). UACR = Malb / Cr-U.

[0155] Blood pressure: Blood pressure was measured after anesthesia, including systolic blood pressure (SBP), diastolic blood pressure (DBP), mean blood pressure (MBP) and heart rate (HR). Once before administration and once on the 58th day of administration (end of administration).

[0156] 2. Secondary efficacy and safety indicators

[0157] Serum potassium: Test once before administration and once at specified times after administration (e.g., once on D14, D28, D45, and D58);

[0158] Glucose and lipid metabolism and liver function: FPG, FRA, LDL-c, HDL-c, TG, TC, ALT, AST, etc., are tested once before administration and at designated times after administration (e.g., once on D28 and D58);

[0159] Hematological indicators: tested once before administration and at specified times after administration (e.g., once on D28 and D58);

[0160] Body weight: once before administration and once every 2 weeks during the administration period;

[0161] After administration, changes in food intake, behavior, etc. were observed for 24 hours every day.

[0162] 3. Sample Collection and Storage

[0163] Blood sample collection method: Before blood collection, the animals were fasted overnight and no anesthesia was used. After the animals were tamed, they were gently squeezed and restrained on the back board, and blood was collected through the forearm vein. After the blood collection, a sterile dry cotton ball was used to gently press the blood collection site to stop the bleeding.

[0164] Urine sample collection method: Animals were fasted overnight before the urine collection operation. On the day of the operation, they were transferred to metabolic cages and all urine excreted within 4 to 6 hours was collected into urine collection bags.

[0165] Sample processing method: see Table 3-1

[0166] Table 3-1 Sample collection and processing information

[0167]

[0168] 4. Detection methods and equipment

[0169] Detection method: See Table 3-2 and Table 3-3

[0170] Blood routine testing instrument: Siemens ADVIA 2120i Hematolagy Systems

[0171] Blood biochemistry and urine index detection instruments: Roche cobas6000 analyzer series C501 module detection, NT-proBNP is detected using ELISA kit.

[0172] Table 3-2 Biochemical test items

[0173]

[0174] Table 3-3 Hematology test items

[0175]

[0176] 5. Blood pressure test

[0177] Testing method: Animals are anesthetized by intramuscular injection of 15mg / kg ketamine hydrochloride. After anesthesia, they are placed in a supine position and cuffs of appropriate size are tied according to the standard. The blood oxygen probe is clamped on the animal's fingers or toes (except the left hand), with the red photosensitive surface on the side of the fingertips. The animal's blood pressure is tested three times in a row in automatic mode, with an interval of 1 minute each time. If the SBP, DBP and MBP of the three blood pressures are not much different (the difference between the highest and lowest values ​​is less than 15mmHg), the test is terminated, otherwise the test continues.

[0178] Test indicators: Test indicators include systolic blood pressure (SBP), diastolic blood pressure (DBP), mean blood pressure (MBP) and heart rate (HR)

[0179] Testing instrument: GE B40i electrophysiological monitor

[0180] 6. Clinical observation

[0181] Number of observations: 1 observation per day.

[0182] Observation method: cage observation

[0183] Observation items: injection site, skin, hair, eyes, ears, nose, mouth, chest, abdomen, urogenital area, limbs, as well as breathing, movement, urination, defecation and behavioral changes.

[0184] 7. Body weight measurement

[0185] Weighing time: before feeding on the day

[0186] Determination method: The animals were fasted for 14 to 16 hours before weighing. The animals were weighed using a large animal scale after entering the transfer cage while awake.

[0187] Measuring instrument: METTLER TOLEDO electronic bench scale

[0188] 8. Data processing

[0189] The experimental results are presented in the form of individual data. Each measurement data is presented as "Mean ± SD" (mean ± standard deviation), and the paired T-test variance analysis method is used to perform statistical analysis on the indicators at each time point before and after administration. P < 0.05 indicates a significant difference and is statistically significant.

[0190] 4. Experimental Results and Discussion

[0191] 1. Effect on proteinuria (UACR)

[0192] Protein in urine increases the osmotic pressure of urine, affects the kidney's concentration function, and damages the function of the glomeruli and renal tubules. Proteinuria is an independent risk factor for glomerular fibrosis. Therefore, controlling UACR in clinical treatment can reduce the risk of renal fibrosis and delay the progression of end-stage renal failure, which is a very important treatment strategy.

[0193] The effects of each group of medication on urinary albumin excretion rate (UACR) are shown in Figure 1 , Figure 2 And Table 4-1. Each group selected DKD rhesus monkeys with moderate to severe increase in proteinuria, as shown by baseline urine albumin / creatinine ratio (UACR): 15mg / g to 350mg / g (4 to 6 hours urine collection) to analyze the changes in UACR at baseline and on D30 and D58 of drug administration. The results are as follows:

[0194] Placebo group (n=4): Compared with the baseline, the UACR (mg / g) at D58 at the end of the trial period increased by an average of 27.16±23.57%; the UACR levels of 4 animals fluctuated stably within a certain range without showing rapid progression.

[0195] Valsartan group (n=4, 3 / 4 mice with moderate to severe proteinuria were included in the statistics): compared with baseline, UACR decreased by about 30% on D30 of drug administration on average, and maintained a significant decrease until D58 when UACR decreased by 40.71±8.27% on average, which was extremely significantly lower than that of the placebo group (p<0.01).

[0196] DOX+PMP+MTP1# experimental group (n=4, 4 / 4 mice with moderate to severe proteinuria were included in the statistics): Compared with baseline, the UACR at D30 after administration decreased by an average of 50.57±23.86%, which was extremely significantly lower than that of the placebo group (p<0.01), and the significant decrease was maintained until the UACR at D58 decreased by an average of 68.75±12.73%, which was extremely significantly lower than that of the placebo group (p<0.01).

[0197] DOX+PMP+MTP2# experimental group (n=4, 3 / 4 patients with moderate to severe proteinuria were included in the statistics): Compared with baseline, the UACR at D30 after administration decreased by an average of 41.56±17.57%, which was extremely significantly lower than that of the placebo group (p<0.01), and the significant decrease was maintained until the UACR at D58 decreased by an average of 42.37±3.50%, which was extremely significantly lower than that of the placebo group (p<0.01).

[0198] In conclusion, administration of DOX+PMP+MTP for 30 days can significantly reduce proteinuria, and the therapeutic effect can be maintained until 58 days after administration, showing a time-effective effect.

[0199] In addition, the UACR experimental data of the additional experiments conducted separately (DOX+MTP group vs. placebo group) are summarized in Table 4-1A. Placebo group (n=3): Compared with the baseline, the UACR (mg / g) at the end of the test period D58 increased by an average of 44.26±52.39.

[0200] DOX+MTP group (n=4): Compared with baseline, the average UACR at D30 after administration increased by 27.10±75.86 (mg / g), which was not statistically different from the placebo group; compared with baseline, the average UACR at D58 after administration increased by 11.44±38.86 (mg / g), which was not statistically different from the placebo group.

[0201] From the experimental data, it can be seen that DOX+MTP administration for 58 days did not show a significant effect in reducing proteinuria in rhesus monkeys with diabetic nephropathy.

[0202]

[0203]

[0204] 2. Impact on glomerular filtration rate (eGFR)

[0205] The effects of each group on eGFR are shown in Figure 3 , Table 4-2 and Table 4-3. eGFR in each group: 30-59 ml / min / 1.73 m 2 The changes in glomerular filtration rate at baseline and after administration on D58 were analyzed.

[0206] Placebo group (n=4): Compared with the baseline, the glomerular filtration rate (eGFR) of the four animals fluctuated stably within a certain range and did not show rapid progression.

[0207] Valsartan group (n = 4, 3 / 4 animals eGFR: 30-59 ml / min / 1.73 m 2 Inclusion in statistics): Compared with the baseline, the average glomerular filtration rate (eGFR) of D58 increased by 10±7ml / min / 1.73m after administration. 2 , which was significantly increased compared with the change value in the placebo group (p<0.05), significantly improved glomerular deterioration, and the therapeutic effect was time-effective.

[0208] DOX+PMP+MTP1# experimental group and 2# experimental group (eGFR: 30-59 ml / min / 1.73 m 2, according to n = 5 statistics, DOX + PMP + MTP1 # experimental group and DOX + PMP + MTP2 # experimental group were combined into one group for analysis): Compared with the baseline, the average glomerular filtration rate eGFR increased by 10 ± 4 ml / min / 1.73 m 2 , which was significantly higher than that of the placebo group (p<0.01), and the therapeutic effect was time-effective.

[0209] In conclusion, administration of D58 to the DOX+PMP+MTP experimental group could significantly improve the glomerular filtration rate eGFR.

[0210] Table 4-2 Effect of DOX+PMP+MTP administration D58 on eGFR in rhesus monkeys with spontaneous chronic diabetic nephropathy

[0211]

[0212] Notes: 1. “a” is relative to baseline.

[0213] Table 4-3 Changes in eGFR in rhesus monkeys with spontaneous chronic diabetic nephropathy after administration of DOX+PMP+MTP on D58

[0214]

[0215] Note: The DOX+PMP+MTP group included animals with eGFR between 30 and 59. 1. “a” is the ratio to baseline. 2. Change value = detection time point - baseline value

[0216] In addition, for the additional experiments conducted separately (DOX+MTP group vs. placebo group), the eGFR experimental data are summarized in Table 4-2A. From the data in Table 4-2A, it can be seen that compared with the placebo group, no significant changes in eGFR were observed after 30 and 58 days of administration of DOX+MTP.

[0217] Table 4-2A Effect of DOX+MTP administration at D58 on eGFR in rhesus monkeys with spontaneous chronic diabetic nephropathy

[0218]

[0219] Notes: 1. “a” is relative to baseline.

[0220] 3. Effects on CysC, Cr-P and BUN

[0221] The effects of drug administration in each group on CysC, Cr-P and BUN are shown in Table 4-4 to Table 4-6. CysC is an endogenous marker that reflects changes in glomerular filtration rate. Cr-P has been used as a major indicator for evaluating renal function for more than 40 years. In this study, glomerular filtration rate eGFR is calculated using CysC and Cr-P. Although BUN is primarily used as an indicator for evaluating renal function, it does not meet the requirements of an endogenous GFR marker and is only used as an auxiliary indicator in this study.

[0222] Table 4-4 Effects of 58-day administration of each group on CysC in rhesus monkeys with spontaneous chronic diabetic nephropathy

[0223]

[0224] Notes: 1. “a” is relative to baseline.

[0225] Table 4-5 Effects of 58-day administration of each group on CR-P in rhesus monkeys with spontaneous chronic diabetic nephropathy

[0226]

[0227] Table 4-6 Effects of 58-day administration of each group on BUN in rhesus monkeys with spontaneous chronic diabetic nephropathy

[0228]

[0229] 4. Effects on Blood Pressure

[0230] The effects of medication on blood pressure in each medication group are shown in Tables 4-7 and 4-8.

[0231] Placebo group (n=4, 2 / 4 hypertension): Compared with the baseline, the blood pressure of the 4 animals fluctuated stably within a certain range.

[0232] Valsartan group (n=4, 2 / 4 hypertension): Compared with baseline, SBP decreased by an average of 13±6 mmHg on D58 after administration, which was significantly lower than that in the placebo group (P<0.05); DBP decreased by an average of 8±5 mmHg, which was extremely significantly lower than that in the placebo group (p<0.01).

[0233] DOX+PMP+MTP 1# experimental group (n=4, 2 / 4 hypertension): Compared with the baseline, the SBP of D58 group was reduced by an average of 10±3 mmHg, and the reduction value was significantly lower than that of the placebo group (P<0.05); DBP did not show a lowering activity. There was no risk of hypotension in animals with normal blood pressure.

[0234] DOX+PMP+MTP 2# experimental group (n=4, 2 / 4 hypertension): Compared with the baseline, the SBP of D58 group was reduced by 5±5 mmHg on average, and the reduction value was not statistically significant compared with the placebo group. DBP did not show lowering activity. The antihypertensive activity was weak.

[0235] In conclusion, the DOX+PMP+MTP combination has a certain high blood pressure lowering activity of 5 to 10 mmHg.

[0236] Table 4-7 Rhesus monkey hypertension classification

[0237]

[0238] Note: When SBP and DBP belong to different grades, the higher grade shall prevail.

[0239] Table 4-8 Effects of 58-day administration of each group on blood pressure in rhesus monkeys with spontaneous chronic diabetic nephropathy

[0240]

[0241] Note: “a” means compared with the placebo group.

[0242] 5. Effect on K+

[0243] The effects of drug administration on K+ in each drug administration group are shown in Tables 4-9. Compared with the baseline period, there was no significant change in the serum K+ level of animals in each test group after administration of D58. In conclusion, there was no risk of hyperkalemia in the DOX+PMP+MTP treatment group after administration of D58.

[0244] Table 4-9 Effects of 58-day administration of each group on K ions in rhesus monkeys with spontaneous chronic diabetic nephropathy

[0245]

[0246] 6. Safety and tolerance study

[0247] As marketed drugs, the safe dosage range and toxic and side effects of DOX, PMP, and MTP are known. The commonly used tablet dosage of DOX is 4 to 8 mg / time, twice a day. The recommended individual dosage of PMP should be 0.375 mg to 4.5 mg per day. When used to treat idiopathic Parkinson's disease, the starting dose is 0.375 mg per day, and then the dose is increased every 5 to 7 days, with a maximum dose of 1.5 mg. The incidence of drowsiness increases when the daily dose is higher than 1.5 mg. The recommended dosage of MTP is 50-200 mg / day, which can reach 300 mg / day or 400 mg / day if necessary. The known adverse reaction is hypotension.

[0248] In this study, the dosage of DOX, PMP and MTP combined to treat chronic diabetic nephropathy in rhesus monkeys was calculated to be the equivalent human dose for clinical patients, which was far lower than the maximum recommended dose mentioned above. Therefore, in theory, the three-drug combination of DOX+PMP+MTP in this application is very safe.

[0249] In addition, no adverse events related to medication were observed during the medication period, and no significant changes were observed in liver function, kidney function, body weight, and biochemical indicators (including FPG, LDL, HDL, TC, TG, ALT, AST, TP, ALB, etc.), further confirming that the DOX+PMP+MTP triple drug combination of the present application does have good biosafety indicators.

[0250] V. Conclusion

[0251] The above experimental results show that oral administration of three GPCR agonists (DOX+PMP+MTP) for 58 days to treat spontaneous diabetic nephropathy rhesus monkeys can significantly reduce moderate to severe proteinuria, significantly improve the deterioration of glomerular filtration rate, and inhibit the occurrence of end-stage renal failure; at the same time, it has good safety and tolerability, and no hyperkalemia and fluid retention were observed during the treatment period.

[0252] VI. Pharmaceutical Composition Example 1

[0253] For a 10 kg monkey, 1.5 mg of Doxazosin mesylate (DOX) raw material powder, 0.02 mg of Pramipexole dihydrochloride (PMP) raw material powder, and 8 mg of Metoprolol tartrate salt (MTP) raw material powder were taken and uniformly mixed to obtain the pharmaceutical composition Example 1. The pharmaceutical composition can be directly mixed into food to feed the animal, or can be prepared into oral tablets after being prepared with appropriate excipients or additives.

[0254] Although the specific implementation methods have been described in detail above, it can be understood by those skilled in the art that, according to the disclosure and guidance of the above description, those skilled in the art to which the present application belongs can also make appropriate changes and modifications to the above implementation methods. Therefore, the present application is not limited to the specific implementation methods disclosed and described above, and some modifications and changes to the present application also fall within the scope of protection of the claims of the present application.

Claims

1. A pharmaceutical composition for treating diabetic nephropathy, wherein the active ingredients are composed of doxazosin or a pharmaceutically acceptable salt thereof, pramipexole or a pharmaceutically acceptable salt thereof, and metoprolol or a pharmaceutically acceptable salt thereof, wherein the weight ratio of metoprolol or a pharmaceutically acceptable salt thereof to doxazosin or a pharmaceutically acceptable salt thereof is in the range of 2:1-30:1, and the weight ratio of pramipexole or a pharmaceutically acceptable salt thereof to doxazosin or a pharmaceutically acceptable salt thereof is in the range of 0.05:1-0.5:

1. The pharmaceutical composition according to claim 1 , which is in an oral dosage form.

3. A pharmaceutical composition according to any one of claims 1 to 2, wherein the pharmaceutically acceptable salt is selected from hydrochloride, sulfate, phosphate, pyrophosphate, hydrobromide or nitrate, citrate, fumarate, maleate, malate, ascorbate, succinate, tartrate, benzoate, acetate, methanesulfonate, ethanesulfonate, salicylate, stearate, benzenesulfonate or p-toluenesulfonate.

4. Use of a combination of doxazosin or a pharmaceutically acceptable salt thereof, pramipexole or a pharmaceutically acceptable salt thereof and metoprolol or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition for treating diabetic nephropathy in a subject in need thereof, wherein the weight ratio of metoprolol or a pharmaceutically acceptable salt thereof to doxazosin or a pharmaceutically acceptable salt thereof is in the range of 2:1-30:1, and the weight ratio of pramipexole or a pharmaceutically acceptable salt thereof to doxazosin or a pharmaceutically acceptable salt thereof is in the range of 0.05:1-0.5:

1. The use according to claim 4 , wherein the pharmaceutical composition is an oral dosage form.

6. The use according to any one of claims 4 to 5, wherein the pharmaceutical composition is suitable for use in primate subjects.

7. The use according to claim 6, wherein the pharmaceutical composition is suitable for use in human subjects.

8. The use according to claim 6, wherein the daily dose of doxazosin or a pharmaceutically acceptable salt thereof ranges from 0.5 mg to 16 mg, the daily dose of pramipexole or a pharmaceutically acceptable salt thereof ranges from 0.05 mg to 4.5 mg, and the daily dose of metoprolol or a pharmaceutically acceptable salt thereof ranges from 5 mg to 200 mg.

9. The use according to claim 6, wherein the daily dose of doxazosin or a pharmaceutically acceptable salt thereof ranges from 0.5 mg to 8 mg, the daily dose of pramipexole or a pharmaceutically acceptable salt thereof ranges from 0.1 mg to 1 mg, and the daily dose of metoprolol or a pharmaceutically acceptable salt thereof ranges from 10 mg to 100 mg.

10. The use according to any one of claims 4 to 5, wherein the pharmaceutically acceptable salt is selected from hydrochloride, sulfate, phosphate, pyrophosphate, hydrobromide or nitrate, citrate, fumarate, maleate, malate, ascorbate, succinate, tartrate, benzoate, acetate, methanesulfonate, ethanesulfonate, salicylate, stearate, benzenesulfonate or p-toluenesulfonate.